hackint0sh/New-Dataset huggingface dataset:
Cryotherapy, therapeutic cooling, is one of the modalities widely used in sports medicine for a variety of treatment purposes. Physiological and neurological responses of musculoskeletal tissues to cooling have been extensively examined in the literature. conditions: Dysmenorrhea Primary studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ACTUAL name: Cryotherapy name: core stability exercises measure: Pain assessed by VAS sex: FEMALE minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Faculty of Physical Therapy,Cairo University city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06320132 id: BLANDISH briefTitle: BLANDISH (Brain, Loss of Function, Aneurism, Disease, Injury, Stroke, Hemorrhage) acronym: BLANDISH overallStatus: RECRUITING date: 2024-03-13 date: 2028-12-31 date: 2029-01-31 date: 2024-03-20 date: 2024-03-20 name: IRCCS Ospedale San Raffaele class: OTHER briefSummary: The goal of this observational study is to train a machine learning system based on data from patients affected by spontaneous Intracranial Hemorrage. The main question it aims to answer is whether there is a correlation between actual clinical pratice, reached outcomes and favorable or unfavorable predictive factors, and anamnesis.
Participants will be treated as per standard clinical practice. conditions: Intracranial Hemorrhages studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 2000 type: ESTIMATED name: Treatment of spontaneous intracranial hemorrhage measure: Mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Ospedale San Raffaele status: RECRUITING city: Milano state: MI country: Italy name: Francesca Guzzo, MD role: CONTACT phone: +393470830669 phoneExt: +390226433333 email: guzzo.francesca@hsr.it name: Margherita Tozzi, MD role: CONTACT phone: +393343138755 phoneExt: +390226433333 email: tozzi.margherita@hsr.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06320119 id: 2943 briefTitle: Setting a PERSONalized Outcome in ASthma: the PERSONAS Study. A Patient Driven Outcome (PDO) Study acronym: PERSONAS overallStatus: RECRUITING date: 2023-01-01 date: 2025-01-15 date: 2025-09-30 date: 2024-03-20 date: 2024-04-11 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER briefSummary: To optimize the effectiveness of asthma therapy there is a need to identify and address individual patient goals. Considering the self-management discussion as central for the achievement of health outcomes, Healthcare Providers may help patients make specific actions to obtain their desired goals.
The current evidence suggest that Healthcare Professionals need to develop a more patient-centered and partnership-based approach based on the development and review of action plans, including the experiential asthma knowledge of patients and caregivers. From a practical perspective, the specialist (i.e. pulmunologists, allergologists, etc) has clear therapeutic targets to be reached in asthmatic patients: for example, improving the disease control, the spirometric values and asthma control test (ACT) score vs. pre-treatment evaluations represent the standard outcomes to reach (GINA 2019). However, as previously described, patients are more likely to achieve an improved clinical outcome when the treatment is driven by a personalized goal. This builds on the same principle as shared decision making between the physician and patient, recognizing both the personal motivation and the accountability on behalf of the patient (Hoskins et al. 2016).
nctId: NCT06320106 id: GIP 1021 briefTitle: Assessment of Navigation Abilities in Children With Cerebral Palsy and Their Peers overallStatus: RECRUITING date: 2023-02-07 date: 2025-01-31 date: 2025-01-31 date: 2024-03-20 date: 2024-03-20 name: IRCCS Eugenio Medea class: OTHER briefSummary: Spatial navigation skills are very important in everyday activities and quality of life but spatial navigation abilities are not part of the standard process of assessment and rehabilitation of patients. Furthermore, it is known that children with cerebral palsy have impaired visuo-spatial competences. The main objective of this study is to evaluate and compare the spatial navigation abilities of typically developing children and of children with cerebral palsy using the "StarMaze" application delivered by means of a Head Mounted Display (HMD). The second aim is to investigate the user experience during the session. A similar application was already developed and tested in a virtual reality large scale platform whose size and cost limit the accessibility. Therefore, the assessment (and future training) of navigation abilities with affordable and easy-to-use technology such as HMD open new perspectives. conditions: Cerebral Palsy conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 26 type: ESTIMATED name: Virtual Reality baseline assessment measure: Navigation strategy measure: Learning rate measure: Simulator Sickness Questionnaire measure: System Usability Scale measure: Independent Television Commission-Sense of Presence Inventory measure: Suitability Evaluation Questionnaire - simplified version measure: Short-form of PANAS-Positive Affect and Negative Affect Scales sex: ALL minimumAge: 13 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Scientific Institute, IRCCS E. Medea status: RECRUITING city: Bosisio Parini state: Lecco zip: 23842 country: Italy name: Emilia Biffi, PhD role: CONTACT phone: +39 31877862 email: emilia.biffi@lanostrafamiglia.it name: Emilia Biffi, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.80075 lon: 9.29 hasResults: False
nctId: NCT06320093 id: INRCA_002_2024 briefTitle: Training Social and Health Care prOfessionals in mUsic-based Therapeutic iNterventions to Support Older People With Dementia acronym: SOUND overallStatus: COMPLETED date: 2023-10-03 date: 2024-02-20 date: 2024-02-20 date: 2024-03-20 date: 2024-03-20 name: Istituto Nazionale di Ricovero e Cura per Anziani class: OTHER name: European Union briefSummary: The study will investigate the effects of an inovative intervention based on the use of music on 45 professionals in the field of dementia, 45 elderly people with dementia. conditions: Dementia conditions: Older People studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 45 type: ACTUAL name: SOUND Intervention measure: Change in mental wellbeing of patients with dementia measure: Change in cognitive status of patients with dementia measure: Change in stress of health care providers sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: INRCA Hospital city: Ancona zip: 60127 country: Italy lat: 43.5942 lon: 13.50337 facility: Sons do Estamine Associacao city: Trofa country: Portugal facility: Associatia Habilitas city: Bucarest country: Romania lat: 44.43225 lon: 26.10626 hasResults: False
nctId: NCT06320080 id: TQB2223-AK105-Ib-01 briefTitle: Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02 date: 2025-10 date: 2024-03-20 date: 2024-03-20 name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. class: INDUSTRY briefSummary: TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. This is a phase Ib study aimed at evaluating the safety, tolerability, and immunogenicity characteristics of TQB2223 injection combined with AK105 injection in the treatment of advanced hepatocellular carcinoma. conditions: Advanced Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 34 type: ESTIMATED name: TQB2223 injection name: Penpulimab Injection measure: Objective Response Rate (ORR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Disease control rate (DCR) measure: Duration of Response (DOR) measure: Number of patients with adverse events (AEs) and/or serious adverse events (SAEs) measure: Immunogenicity sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affiliated Cancer Hospital of Harbin Medical University city: Harbin state: Heilongjiang zip: 150000 country: China name: Zhiwei Li, Doctor role: CONTACT phone: 15004683651 email: lzhw0451@163.com lat: 45.75 lon: 126.65 facility: Hubei Provincial Tumor Hospital city: Wuhan state: Hubei zip: 430079 country: China name: Feng Zhang, Doctor role: CONTACT phone: 13871410719 email: zhangfeng_329@126.com lat: 30.58333 lon: 114.26667 facility: Hunan Provincial Tumor Hospital city: Changsha state: Hunan zip: 410031 country: China name: Shanzhi Gu, Master role: CONTACT phone: 13574865998 email: 105575191@qq.com lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06320067 id: PR12 id: 1006437 type: OTHER domain: IRAS briefTitle: A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer acronym: STAMPEDE2 overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2031-04 date: 2034-03 date: 2024-03-20 date: 2024-03-20 name: University College, London class: OTHER name: Cancer Research UK name: Novartis name: Janssen Pharmaceutica NV briefSummary: STAMPEDE2 is a clinical trial comparing three new treatments with standard of care in people with prostate cancer that has spread to other parts of the body and is responsive to hormone therapy. People from all backgrounds and ethnicities are encouraged to take part and multiple hospitals across the UK are involved. University College London is running the trial.
Comparison N: Arm A(N) versus Arm N (Niraparib-Abiraterone Acetate+Prednisolone (Nira-AA+P)) - Tests whether giving a new drug (Nira-AA+P) slows the spread of the cancer and improves survival. Only people with certain genetic changes in their tumour sample can take part in Comparison N. 682 people will be in this comparison.
All participants will be followed up with scans and tests to monitor their cancer. Doctors will check for any side effects from the treatments. Treatments will be stopped if side effects are serious, or people no longer wish to take the treatments. conditions: Prostate Cancer Metastatic studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Platform trial testing three research comparisons where patients are randomised either to experimental treatments in Arms S, P and N or their corresponding SoC control Arms A and A(N). primaryPurpose: TREATMENT masking: NONE count: 8000 type: ESTIMATED name: Stereotactic Ablative Body Radiotherapy (SABR) name: 177Lu-PSMA-617 name: Niraparib and Abiraterone Acetate Dual Action Tablet DAT name: Abiraterone Acetate name: Apalutamide name: Androgen Deprivation Therapy (ADT) name: Androgen Receptor Signalling Inhibitor (ARSI) name: Local Radiotherapy name: Prednisolone name: Docetaxel measure: Radiographic Progression-Free-Survival (rPFS) measure: Overall Survival (OS) measure: Failure-Free Survival (FFS) measure: Prostate cancer specific survival (PCSS) measure: Safety through reporting of SAEs measure: Toxicity using CTCAE classification and reporting of all Adverse Events that are ≥ grade 3 or grade 1 and 2 leading to a change in trial treatment measure: Compliance with randomised allocation. Formal definitions for compliance with treatment will be pre-specified in the statistical analysis plan. This is still in development. measure: EQ-5D-5L questionnaire for QoL and cost effectiveness assessment sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06320054 id: PRO00049771 briefTitle: Preventing Obstetric Complications With Dietary Intervention acronym: PLATE overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-30 date: 2025-08-31 date: 2024-03-20 date: 2024-03-20 name: Medical College of Wisconsin class: OTHER name: Advancing a Healthier Wisconsin Endowment name: Food for Health, Inc. briefSummary: The goal of this study is to learn whether access to healthy and fresh food, health coaching, and nutrition support intervention can reduce adverse birth outcomes in pregnant women. The main questions it aims to answer are:
Researchers will compare the standard of care to those who receive the intervention to see the impact of the intervention on clinical outcomes including: gestational weight gain, blood pressure, diagnosis of gestational diabetes, diagnosis of gestational hypertension or preeclampsia, and gestational age at birth. conditions: Gestational Diabetes conditions: Gestational Hypertension conditions: High Risk Pregnancy conditions: Preeclampsia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Maternal Health Management Program measure: Clinical Outcomes measure: Clinical Outcomes measure: Clinical Outcomes measure: Clinical Outcomes measure: Clinical Outcomes measure: Patient Reported Outcomes measure: Patient Reported Outcomes measure: Patient Reported Outcomes measure: Patient Reported Outcomes measure: Patient Reported Outcomes sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06320041 id: KY-2024-028 briefTitle: Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-12-30 date: 2024-12-31 date: 2024-03-20 date: 2024-03-20 name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine class: OTHER briefSummary: The goal of this clinical trial\] is to further explore the effectiveness and safety of oxelidine in the treatment of moderate to severe acute pain after orthopedic surgery. The main question it aims to answer is: Pain management after orthopaedic surgery provides more effective and safe drug options, provides new options for clinical treatment, and provides a scientific basis for clinical practice.
Participants will be asked to pain score in the different time, treatments they'll be given and use optimal drug. Researchers will compare analgesic effect of oxelidine of different dose. conditions: Postoperative Pain studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 162 type: ESTIMATED name: Low dose oxelidine group name: High dose oxelidine group name: Hydromorphone group measure: Pain score at rest 0-72 hours after surgery measure: The total amount of opioid after operation. measure: PCIA as a remedial analgesic press time sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06320028 id: 019782-00001 briefTitle: Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms acronym: DMNtFUS overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-27 date: 2024-01-03 date: 2024-06-03 date: 2024-03-20 date: 2024-03-20 name: University of Arizona class: OTHER name: Openwater briefSummary: Depression is a leading cause of disability worldwide, affecting roughly 21 million adults. Repetitive Negative Thought (RNT) has been identified as a potential maintaining factor in depression, such that those who exhibit higher degrees of RNT endorse greater symptoms. Research also suggests that the Default Mode Network (DMN), responsible for self-referential processing, plays an important role in depression wherein it has been linked to RNT. In depressed individuals, this network appears to be hyper-connected, or "too connected", within itself which, in turn, is thought to promote RNT.
Half of depressed individuals are treatment-resistant, creating a critical need to identify more effective interventions derived from a better mechanistic understanding of the development and maintenance of depression. Non-invasive Transcranial-Focused Ultrasound Stimulation (tFUS) is promising for the treatment of depression. tFUS directs a low-intensity (nonthermal) focused ultrasound beam that passes safely through the skull. Compared to other noninvasive neuromodulation approaches, tFUS can target deeper brain regions with high spatial precision.
The present study is an exploratory non-blinded single treatment study to investigate whether tFUS targeting a major hub of the DMN, the anterior-medial prefrontal cortex, can improve depression symptoms and reduce RNT. Twenty depressed individuals with high RNT (75th percentile) will complete up to eleven ultrasound sessions targeting the anterior medial prefrontal cortex, a hub of the brain's default mode network that has been found to be hyper-connected in depression. MRI scans will be obtained before the first and after the last ultrasound sessions. Based on previous literature, it is predicted that depression interview ratings and self-report symptoms will decrease after the intervention, and also that DMN connectivity will decrease following intervention. conditions: Depressive Disorder, Major conditions: Depression studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All participants will receive the same treatment protocol. primaryPurpose: TREATMENT masking: NONE maskingDescription: There is no masking. count: 20 type: ACTUAL name: Non-Invasive Transcranial Focused Ultrasound measure: Beck Depression Inventory - II (BDI-II) measure: Perseverative Thinking Questionnaire (PTQ) measure: Hamilton Depression Rating Scale (HDRS) measure: Default Mode Network (DMN) Connectivity measure: The Montgomery-Åsberg Depression Rating Scale (MADRS) sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: University of Arizona city: Tucson state: Arizona zip: 85721 country: United States lat: 32.22174 lon: -110.92648 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2024-01-13 uploadDate: 2024-03-13T20:19 filename: SAP_000.pdf size: 123058 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2022-12-22 uploadDate: 2024-01-17T15:37 filename: ICF_001.pdf size: 159488 hasResults: False
nctId: NCT06320015 id: R01CE003632-01-00 id: R01CE003632 type: NIH link: https://reporter.nih.gov/quickSearch/R01CE003632 briefTitle: Emergency Medicine Peer Outreach Worker Engagement for Recovery acronym: EMPOWER overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2025-01 date: 2025-09 date: 2024-03-20 date: 2024-03-20 name: University of California, Los Angeles class: OTHER name: Rhode Island Hospital name: The Miriam Hospital name: Brown University briefSummary: This is an observational, prospective case-control study evaluating the effects of an emergency department community health worker-peer recovery specialist program (PCHW), the Substance Misuse Assistance Response Team (SMART). Aims of this study are to 1) understand participant experiences working with a SMART PCHW and identify possible mechanisms for successful recovery linkage; 2) Evaluate SMART effectiveness on patient-centered outcomes, building recovery capital, and recovery linkage; 3) Evaluate SMART implementation and effectiveness on patient outcomes over time.
Using a combination of surveys and data linkages to state administrative databases, study investigators will prospectively compare changes in addiction treatment engagement, recovery capital, health related social needs, acute care utilization, and death between people receiving a ED PCHW and those who do not. After consenting to study participation, participants will complete surveys at time of study enrollment and 3 and 6 months after their initial ED visit. Primary outcomes include engagement in addiction treatment, social services engagement, acute care utilization, and mortality will be assessed through linkages to state administrative databases. conditions: Substance Use Disorders conditions: Overdose conditions: Opioid Use Disorder conditions: Alcohol Use Disorder studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 400 type: ESTIMATED name: Substance Misuse Assistance Response Team (SMART) measure: Treatment engagement measure: Recovery Capital measure: Emergency Department Utilization measure: Repeat Hospitalization measure: Repeat Overdose measure: Mortality measure: Social Services Engagement measure: Housing Services Engagement measure: Employment measure: Incarceration sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06320002 id: 2023P003564 briefTitle: Communication Intervention for Fecal Ostomy Surgery acronym: CI-oSurg overallStatus: RECRUITING date: 2024-03-18 date: 2024-07-31 date: 2024-08-30 date: 2024-03-20 date: 2024-03-28 name: Massachusetts General Hospital class: OTHER briefSummary: In this study the investigators will evaluate the acceptability of a communication intervention for fecal ostomy surgery (CI-oSurg) to address the needs of adults who are undergoing fecal ostomy surgery. The investigators will recruit 24 patients and 4 clinicians (surgical nurses, wound ostomy nurses). At least half of patients are 65 years or older to understand the unique needs of older adults recovering from fecal ostomy surgery that might impact intervention acceptability. Questionnaires will be administered at two time-points for patient participants: upon study start and 4 weeks after exposure to the intervention. conditions: Surgery conditions: Colostomy Stoma conditions: Ileostomy - Stoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 28 type: ESTIMATED name: Communication Intervention for fecal ostomy surgery measure: Intervention Acceptability measure: Intervention Usability measure: Emotional Distress measure: World Health Organization Brief quality of life evaluation measure: Hospital Anxiety and Depression Scale measure: Therapy Evaluation Form measure: Client Satisfaction Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Massachusetts General Hospital status: RECRUITING city: Boston state: Massachusetts zip: 02114 country: United States name: Christy E Cauley, MD role: CONTACT phone: 617-726-8129 email: ccauley@mgb.org lat: 42.35843 lon: -71.05977 hasResults: False